Actualités et vidéos - ORGANON & CO ORGANON ORD SHS (CDI)

Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon’s Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board’s Talent Committee. In connection with Ms. Sequeira’s appointment, the size of Organon’s Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of...

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of...

Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (Nasdaq: BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE ™ , a biosimilar to ACTEMRA ® , for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant...

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered Adjusted EBITDA margin expansion ex-IPR&D,” said Kevin Ali, Organon's chief executive officer. “Our 2025 financial guidance reflects the potential for a fourth year of constant currency revenue growth despite the loss of exclusivity (LOE) of our second largest product, Atozet, in certain markets....

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2024 financial results on February 13, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to the company’s quarterly...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at:...

U.S. grant programs include: Funding for select community health clinics in contraceptive deserts in Texas, Ohio and Georgia and product donations for Direct Relief's clinic network Ambassador program through Power to Decide to address the sexual and reproductive health needs of students at five Historically Black Colleges and Universities (HBCUs) NORTHAMPTON, MA / ACCESSWIRE / February 20, 2024 / Today, Organon (NYSE:OGN), a global healthcare company with a focus on women's health, embarks on...

Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023. "During the second quarter of 2023, Organon continued to build on its track record, delivering solid volume growth across all regions and franchises. The Women's Health and Biosimilars franchise revenue grew 10% and 15% excluding the impact of foreign currency ("ex-FX"), respectively, and Established Brands continued to demonstrate stability," said Kevin Ali, Organon's CEO. "Further, on July 1 st we...

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ . A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website....

Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States. Consistent with Humira, HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) to provide patients with seamless continuity of care. This press release features multimedia. View the full release here:...

Organon (NYSE : OGN), une entreprise mondiale de soins de santé orientée vers la santé des femmes, a publié aujourd'hui son rapport environnemental, social et de gouvernance (ESG) pour 2022-2023. Le rapport souligne les progrès réalisés par l'entreprise sur sa plateforme ESG complète Her Promise , en toute conformité avec les objectifs de développement durable (ODD) des Nations unies. « Chez Organon, notre objectif se nourrit de la promesse faite par les quatre milliards de femmes et...

Organon (NYSE: OGN), una empresa líder del mundo del sector de salud dedicada a la salud de las mujeres, publicó hoy el informe sobre los aspectos ambiental, social y de gobierno corporativo (ASG) para 2022-2023. El informe destaca el progreso de la empresa respecto de su plataforma integral de ASG llamada Her Promise y de los objetivos relacionados, que están en línea con los objetivos de desarrollo sostenible de las Naciones Unidas (ODS). "En Organon, alimentamos nuestro propósito a...

Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report . The report highlights the company’s progress on its comprehensive ESG platform, Her Promise , and its related goals, which are in line with the United Nations Sustainable Development Goals (SDGs). “At Organon, our purpose is fueled by the promise held by the four billion women and girls in the world,” said Kevin Ali, Organon CEO....

Aujourd’hui, Organon (NYSE : OGN), une société mondiale de soins de santé axée sur la santé des femmes, et la CAF, la Banque de développement d’Amérique latine, ont signé un protocole d’accord pour contribuer aux objectifs de développement durable des Nations unies par la conception, la structure et la mise en œuvre de programmes durables qui encouragent et améliorent l’équité, la santé et l’autonomie des filles et des femmes en Amérique latine et dans les Caraïbes....

Hoy, Organon (NYSE:OGN), empresa internacional del sector de la medicina enfocada en la salud de la mujer, y CAF, Banco de Desarrollo de América Latina, firmaron un memorando de entendimiento (MOU, por sus siglas en inglés) para contribuir a los Objetivos de Desarrollo Sostenible de las Naciones Unidas a través del diseño, la estructuración e implementación de programas sostenibles que promuevan y mejoren la equidad, la salud y la autonomía de niñas y mujeres en América Latina y el...

Today, Organon (NYSE:OGN), a global healthcare company focused on women’s health, and CAF, Development Bank of Latin America, signed a memorandum of understanding (MOU) to contribute to the United Nations Sustainable Development Goals through the design, structure and implementation of sustainable programs that promote and improve equity, health and autonomy of girls and women in Latin America and the Caribbean. Across the globe, tremendous gaps exist in women’s health that can potentially...

Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2023. "The first quarter of 2023 represents the sixth consecutive quarter of constant currency product sales growth, with all three franchises positively contributing to performance," said Kevin Ali, Organon's CEO. "The Established Brands franchise, which represents two-thirds of our business, continues to demonstrate its durability. The associated predictability of cash flows enables us to take a balanced...

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ . A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website....

Organon (NYSE: OGN), une société internationale de soins de santé axée sur l’amélioration de la santé des femmes, a annoncé aujourd’hui le lancement d’une nouvelle initiative mondiale, «Her Plan is Her Power», pour contribuer à la résolution du problème de santé publique que représentent les grossesses non désirées. Chaque année, on estime que près de 50% des grossesses (environ 121 millions) dans le monde ne sont pas intentionnelles, ce qui entraîne des risques pour la...

Organon (NYSE: OGN), una empresa global de atención médica centrada en mejorar la salud de las mujeres, ha anunciado hoy el lanzamiento de una nueva iniciativa global, «Su plan es su poder» (en inglés, Her Plan is Her Power), para acelerar el progreso hacia la solución de la crisis de salud pública que suponen los embarazos no planificados. Se calcula que, cada año, cerca del 50 % de los embarazos (aproximadamente 121 millones) en todo el mundo no son planificados, lo que conlleva...